About NHSi
New Health Sciences, Inc. is developing and commercializing two, strategically linked
technologies. Hemodyanamic Vascular Analysis (HVA) is a safe, precise and inexpensive
method for diagnosing and managing neurovascular disease. HVA is the only quantitative,
sensitive, reproducible physiological means of measuring and describing changes
in vascular function that signal the presence or risk of cerebral vascular disease.
Hemanext, is a novel technology that delivers red blood cells (RBCs) of higher efficacy
for transfusion therapy, and at the same time, extends the shelf life of refrigerated
RBCs.
NHSi Technologies
Hemodynamic
Vascular Analysis Hemanext
News
May 26, 2009—New Health Sciences Inc.
(NHSi) has won a two-year award of $1.9 million from the National Heart, Lung and
Blood Institute of the National Institutes of Health (NIH) to develop a groundbreaking
blood-storage system.
Read More
December 1, 2008 – Hemanext Patent Application 10/377.178 for Microvascular
Network Device Allowed by US Patent and Trademark Office
On December 1, 2008 the NHSi received notification from the USPTO that Hemanext
patent application number 10/377,178 for Microvascular Network Device was allowed
for issuance as a patent.
Read More
March 2009 – Hemanext Trial Results Published in Transfusion
The results of NHSi’s Phase I Hemanext Anaerobic Storage Platform (HASP) trial have
been accepted for publication in Transfusion.
Read More